Skip to main content
Log in

Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

It has been shown that the hallucinogenic potencies of LSD, the phenylisopropylamines, such as DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) and DOI (4-iodo-2,5-dimethoxyphenylisopropylamine), and the indoleaklylamines, such as DMT (dimethyltryptamine) and 5-OMe-DMT (5-methoxy-dimethyltryptamine), strongly correlate with their in vitro 5-HT2 receptor binding affinities in rat cortical homogenates. In order to ascertain if this correlation applies to human 5-HT2 receptors as well, we examined the affinities of 13 psychoactive compounds at 3H-ketanserin-labelled 5-HT2 receptors in human cortical samples. Both radioligand binding and autoradiographical procedures were used. As in rat brain d-LSD was the most potent displacer of 3H-ketanserin specific binding with a K i of 0.9 nM. The phenylisopropylamine DOI also displayed high affinity (K i of 6 nM). Stereospecific interactions were found with DOB; (-_ DOB had a K i of 17 nM while (+) DOB had a K i of 55 nM. The behaviorally active compound DOM (4-methyl-2,5-phenylisopropylamine) had an affinity of 162 nM while its behaviorally less active congener iso-DOM had an affinity of 6299 nM. The indolealkylamines 5-OMe-DMT and DMT competed with moderate affinities (207 and 462 nM, respectively). In general, Hill coefficients were significantly less than unity which is consistent with an agonist interaction with 5-HT2 receptors. MDMA, a substituted amphetamine analog was inactive with a K i of greater than 10 μM. A strong correlation was found for the hallucinogen affinities and human hallucinogenic potencies (r=0.97). Also, human and rat brain 5-HT2 receptor affinities were strongly correlated (r=0.99). These results strongly support the hypothesis that the hallucinogenic effects of these drugs in humans are mediated in whole or in part via 5-HT2 receptors. Furthermore, these studies imply that treatment with 5-HT2 receptor antagonists may be effective in reversing the hallucinogenic effects caused by the ingestion, of LSD and LSD-like drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Battaglia G, Shannon M, Bordundvaag B, Titeler M (1983) Properties of 3H-prazosin-labelled alpha-1 receptors in rat brain and porcine neurointermediate lobe. J Neurochem 41:538–542

    Google Scholar 

  • Glennon RA, Young R, Rosecrans JA, Anderson GM (1982) Discriminative stimulus properties of MDA analogs Biol Psychiatry 17:807–814

    Google Scholar 

  • Glennon RA, Young R, Rosecrans JA (1983) Antagonism of the effects of the hallucinogen DOM and the purported 5-HT agonist quipazine by 5-HT2 antagonists. Eur J Pharmacol 91:189–196

    Google Scholar 

  • Glennon RA, Rosecrans JA, Young R (1984a) Drug-induced discrimination: a description of the paradigm and a review of its specific application to the study of hallucinogenic agents. Med Res Rev 3:289–376

    Google Scholar 

  • Glennon RA, Titeler M, McKenney JD (1984b) Evidence for 5-HT2 receptor involvement in the mechanism of action of hallucinogenic agents. Life Sci 35:2205–2211

    Google Scholar 

  • Glennon RA, Seggel MR, Soine WH, Herrick-Davis K, Lyon RA, Titeler M (1988) 125I-1-(2,5-Dimethoxy-4-iodophenyl)-2-amino-propane: an iodinated radioligand that specifically labels the agonist high affinity state of 5-HT2 serotonin receptors. J Med Chem 31:5–7

    Google Scholar 

  • Hoyer D, Karpf A (1988) 125I-SCH 23982, a “selective” D1 receptor antagonist labels with high affinity 5-HT1C sites in pig choroid plexus. Eur J Pharmacol 150:181–184

    Google Scholar 

  • Leysen JE, Eens A, Gommeren W, Gompel PV, Wynants J, Janssen PAJ (1987) Nonserotonergic 3H-ketanserin binding sites in striatal membranes are associated with a dopac release system on dopaminergic nerve endings. Eur J Pharmacol 134:373–375

    Google Scholar 

  • Lyon RA, Glennon RA, Titeler M (1986) 3,4-Methylenedioxy-methamphetamine (MDMA): Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacology 88:525–526

    Google Scholar 

  • Lyon RA, Davis KH, Titeler M (1987) 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide sensitive state of cortical 5-HT2 receptors. Mol Pharmacol 31:194–199

    Google Scholar 

  • Lyon RA, Titeler M, Seggel MR, Glennon RA (1988) Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens. Eur J Pharmacol 145:291–297

    Google Scholar 

  • McPherson GA (1983) A practical computer-based approach to the analysis of radioligand binding experiments Comput Programs Biomed 17:107–114

    Google Scholar 

  • Rasmussen K, Aghajanian GK (1986) Effect of hallucinogens on spontaneous and sensory-evoked locus coeruleus unit activity in the rat: reversal by selective 5-HT2 antagonists. Brain Res 385:395–400

    Google Scholar 

  • Shannon M, Battaglia G, Glennon RA, Titeler M (1984) 5-HT1 and 5-HT2 binding properties of the hallucinogen 1-(2,5-dimethoxyphenyl)2-aminopropane (2,5 DMA). Eur J Pharmacol 102:23–29

    Google Scholar 

  • Shulgin A (1978) Psychotomimetic drugs: structure-activity relationships. In: Iversen LL, Iversen S, Snyder S (eds) Handbook of psychopharmacology. Plenum Press, New York

    Google Scholar 

  • Titeler M, Herrick K, Lyon RA, McKenney JD, Glennon RA (1985) 3H-DOB: a specific agonist radioligand for 5-HT2 serotonin receptors. Eur J Pharmacol 117:145–146

    Google Scholar 

  • Titeler M, Lyon RA, Glennon RA (1988) Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens. Psychopharmacology 94:213–216

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sadzot, B., Baraban, J.M., Glennon, R.A. et al. Hallucinogenic drug interactions at human brain 5-HT2 receptors: implications for treating LSD-induced hallucinogenesis. Psychopharmacology 98, 495–499 (1989). https://doi.org/10.1007/BF00441948

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00441948

Key words

Navigation